Pacific Biosciences of California Inc
General ticker "PACB" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $539.1M
Pacific Biosciences of California Inc does not follow the US Stock Market performance with the rate: -22.9%.
Estimated limits based on current volatility of 4.8%: low 1.81$, high 1.99$
Factors to consider:
- North America accounted for 52.6% of revenue in the fiscal year ended 2023-12-31
- Current price 64.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [5.49$, 13.08$]
- 2024-12-30 to 2025-12-30 estimated range: [5.20$, 12.49$]
Financial Metrics affecting the PACB estimates:
- Negative: Non-GAAP EPS, $ of -1.11 <= 0.10
- Negative: Operating profit margin, % of -62.52 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -10.14 <= 2.35
- Negative: Inventory ratio change, % of 4.71 > 1.08
- Negative: Industry operating cash flow per share per price (median), % of 0.50 <= 3.85
- Negative: Industry earnings per price (median), % of -3.50 <= 1.31
- Positive: Interest expense per share, $ of 0.06 <= 0.14
Short-term PACB quotes
Long-term PACB plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $61.51MM | $128.30MM | $200.52MM |
| Operating Expenses | $271.94MM | $433.12MM | $534.99MM |
| Operating Income | $-210.44MM | $-304.82MM | $-334.47MM |
| Non-Operating Income | $-64.44MM | $-9.43MM | $16.31MM |
| Interest Expense | $12.53MM | $14.69MM | $14.34MM |
| R&D Expense | $112.90MM | $193.00MM | $187.17MM |
| Income(Loss) | $-274.87MM | $-314.25MM | $-318.16MM |
| Taxes | $-93.65MM | $-17.32MM | $-11.42MM |
| Profit(Loss) | $-181.22MM | $-296.93MM | $-306.74MM |
| Stockholders Equity | $790.99MM | $562.90MM | $701.30MM |
| Inventory | $24.60MM | $50.38MM | $56.68MM |
| Assets | $2,006.97MM | $1,767.09MM | $1,746.01MM |
| Operating Cash Flow | $-111.18MM | $-263.21MM | $-259.17MM |
| Capital expenditure | $5.93MM | $16.93MM | $8.84MM |
| Investing Cash Flow | $-678.53MM | $116.08MM | $4.60MM |
| Financing Cash Flow | $1,169.58MM | $9.62MM | $108.89MM |
| Earnings Per Share* | $-0.89 | $-1.32 | $-1.21 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.